Cargando…
Correction to: The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition
Autores principales: | Shimoi, Tatsunori, Nagai, Shigenori E., Yoshinami, Tetsuhiro, Takahashi, Masato, Arioka, Hitoshi, Ishihara, Mikiya, Kikawa, Yuichiro, Koizumi, Kei, Kondo, Naoto, Sagara, Yasuaki, Takada, Masahiro, Takano, Toshimi, Tsurutani, Junji, Naito, Yoichi, Nakamura, Rikiya, Hattori, Masaya, Hara, Fimikata, Hayashi, Naoki, Mizuno, Toshiro, Miyashita, Minoru, Yamashita, Nami, Yamanaka, Takashi, Saji, Shigehira, Iwata, Hiroji, Toyama, Tatsuya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Singapore
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213656/ https://www.ncbi.nlm.nih.gov/pubmed/33886078 http://dx.doi.org/10.1007/s12282-021-01252-x |
Ejemplares similares
-
The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition
por: Shimoi, Tatsunori, et al.
Publicado: (2020) -
First-line endocrine therapy for postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysis
por: Shimoi, Tatsunori, et al.
Publicado: (2020) -
The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 edition
por: Terada, Mitsuo, et al.
Publicado: (2023) -
Pertuzumab retreatment for HER2‐positive advanced breast cancer: A randomized, open‐label phase III study (PRECIOUS)
por: Yamamoto, Yutaka, et al.
Publicado: (2022) -
Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD)
por: Yamashita, Toshinari, et al.
Publicado: (2020)